MALAT1 and chronic myelomonocytic leukemia: Furthermore, exploring nuclear scaffold lncRNA MALAT1 therapeutic candidacy in CML, Balasis and coworkers tested the consequences of MALAT1 antisense oligonucleotides (ASOs) and all-trans retinoic acid (ATRA) combination treatment in CMML patient-derived xenografts.